Menu
No results found.
ABVX
ABIVAX Société Anonyme – EPA
Weekly Share Price & Valuation Overview
Market Overview
Open
60.8000
Close
60.7000
High
61.2000
Low
59.0000
Trend
0.67821
ABIVAX Société Anonyme
France
• EPA - Euronext Paris
• ABVX
• Currency: EUR
ABIVAX Société Anonyme, a clinical-stage biotechnology company, focuses on developing therapeutics that harness the body's natural regulatory mechanisms to stabilize the immune response in patients with chronic inflammatory diseases. Its lead drug candidate includes obefazimod that is in Phase 3 clinical trials for the treatment of adults with moderately to severely active ulcerative colitis, as well as in Phase 2b clinical trial to treat patients with Crohn's disease. The company was incorporated in 2013 and is headquartered in Paris, France.
Key strengths
- High gross margin (≥35%) suggests strong pricing power or cost control.
- Earnings growth ≥10% supports improving profitability trajectory.
- Quick ratio ≥1.0 indicates obligations can be met without inventory.
Potential weaknesses
- Negative free cash flow — operations may rely on external financing.
Scale & Structure
Core size and share structure. TTM values unless noted. “Estimated” where reconciled from per-share × shares.
- Market Cap Total equity value of the company (share price × shares outstanding).
- EUR 4.53B
- Enterprise Value Operating value: market cap + total debt − cash.
- EUR 3.81B
- Total Revenue (TTM) Sales over the last twelve months. May be estimated from revenue per share when inconsistent.
- EUR 10.59M
- Revenue per Share (TTM) Total revenue divided by shares outstanding (may be estimated).
- EUR 0.17
- EPS (TTM) Earnings per share over the last twelve months (may be estimated from net income ÷ shares).
- -2.95
- Shares Outstanding
- 75.57M
- Float Shares
- 30.31M
- Implied Shares Outstanding
- 76.47M
Profitability & Efficiency
TTM basis. “Reconciled” = numerator ÷ TTM revenue. EBITDA suppressed where implausible vs revenue.
- Operating Margin (TTM) Operating income ÷ revenue over the last twelve months (reconciled when possible).
-
-48.66%
- Gross Margin (TTM) Strong Gross profit ÷ revenue over the last twelve months (reconciled when possible).
-
100.00%
- ROA Return on assets: net income ÷ total assets.
-
-48.60%
- ROE Return on equity: net income ÷ shareholder equity.
-
-1.96%
Growth
Growth rates are YoY unless labeled QoQ.
- Revenue Growth Year-over-year revenue growth.
-
-17.40%
- Earnings Growth (YoY) Strong Year-over-year earnings growth.
-
30.00%
Liquidity & Solvency
Balance-sheet health. Debt metrics shown as latest ratios; D/E is a ratio (not %).
- Quick Ratio Adequate Liquid current assets ÷ current liabilities (ex-inventory).
- 1.16
- Total Cash Cash and equivalents.
- EUR 103.58M
- Total Debt Short + long-term interest-bearing debt.
- EUR 106.56M
- Net Debt Total debt − cash (negative = net cash).
- EUR 2.99M
Sharemaestro House View
Confidence: 1
Sharemaestro internal conviction (0–3, higher is better).
Risk: 3
Sharemaestro internal risk profile (0–3, higher is safer).
Composite Score: 1
Overall internal composite (0–3, higher is better).
Suggested Allocation: 1.67%
Indicative portfolio weighting suggestion based on house view.
Structural Insights
(experimental)
Ownership & Liquidity
Free Float
Proportion of shares available for public trading.
40.1%
Insiders
Shares held by company insiders (officers, directors).
0.7%
Institutions
Shares held by institutions (funds, pensions).
50.3%
Capital Structure
Potential Dilution
Increase in share count if options/convertibles exercise.
1.2%
Net Debt
Total debt − cash (negative = net cash).
EUR 2.99M
28.2% of revenue
Net debt relative to revenue — debt load vs business scale.
Resilience Score
0–100 composite of liquidity, leverage and cash conversion; higher is better. If inputs are unavailable, we estimate using proxies (Net debt vs revenue, Cash-to-Debt). It is a guide, not a rating.
66
Methodology Notes
- EBITDA & EBITDA margin suppressed (implausible vs revenue or not meaningful for financials).
As of: 2025-08-18 03:18
Disclaimer: Information is compiled from publicly available sources and is subject to errors and omissions. It is provided as a guide only and does not constitute investment advice. Please do your own research.
AI generated insights not available yet. Sign in to generate the snapshot.